According to J.P. Morgan, after strong 1Q results, they are raising the price target on Allergan AGN to $83.00 from $80.00 and are maintaining the neutral rating.
In the report, J.P. Morgan said, "Allergan reported solid 1Q/11 results (+$0.03 EPS beat despite higher than expected SG&A spend) driven by strong ophthalmology product sales and impressive results from the filler franchise. Based on these results, we see upside to both AGN's top-line and EPS targets and our 2011 estimate of $3.66 is above the new range ($3.56-3.62)."
AGN closed yesterday at $81.87.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in